Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionSOPHiA GENETICS SA Ordinary Shares (SOPH)
Fair value
Not available
ACCE price target
$5.99
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $7.35 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
50
out of 100
Analysts
100% buy
5 covering
1-year return
+78.4%
Dividend yield
0.00%
SOPHiA GENETICS SA Ordinary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
SOPHiA GENETICS sells cloud-based software that turns raw sequencing and imaging data into clinical reports, with its SOPHiA DDM platform used by hospitals and labs for oncology and rare-disease genomics. Its moat is the installed base and data network: once a lab validates a workflow on the platform, switching is costly, and the company earns a 66.6% gross margin, consistent with software economics. Revenue growth of 27.2% is the bull case, and the question is whether operating leverage arrives before the balance sheet is tested, since the operating margin is still -86.0% and ROE is -101.2%. At a 621M USD market cap, the stock is priced as a growth story rather than a earnings story, with no P/E to anchor it. It scores 50/100 and sits outside any major index, so it is a candidate for a deeper look only if the margin trajectory in the next few reporting periods is visibly narrowing.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
high
Cash burn against small market cap
Free cash flow is -$38.6M with a -86.0% operating margin and debt/equity of 1.34. At a $573M market cap, the balance sheet needs close watching for further dilution or refinancing.
moderate
Price above ACCE target
The stock trades 22.7% above the ACCE price target of $5.99, with the price at $7.35. Growth is positive, but the valuation already assumes more than our target does.
AI research notes
AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 27.2% year over year, and has averaged 22.2% growth per year over five years.
The analysts' mean target sits 44.9% above the current $7.35 share price, pointing to upside on their numbers.
Why it could disappoint
Net margin is -93.9% and the company lost money on a per-share basis, with EPS of -0.26 against -0.15 expected.
Free cash flow over the last twelve months was -$39M, and the free cash flow yield is -6.7%.
Debt to equity of 1.34 and a diluted share count up 2.7% add financial strain and dilution for existing holders.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 3, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where SOPH's valuation models land
Price
$7.35
Model fair valueConfidence: low
about $6.78
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores